v3.25.2
STOCK-BASED COMPENSATION - Summary of RSUs and PSUs (Details) - shares
6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Outstanding at beginning of period (in shares) 1,460,702    
Granted (in shares) 618,896    
Vested and Released (in shares) (688,206)    
Forfeited (in shares) (39,167)    
Outstanding at end of period (in shares) 1,352,225 1,460,702  
Vested and deferred (in shares) 8,453    
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Outstanding at beginning of period (in shares) 339,268    
Granted (in shares) 86,911    
Vested and Released (in shares) (133,034)    
Forfeited (in shares) (21,138)    
Outstanding at end of period (in shares) 272,007 339,268  
Vested and deferred (in shares) 0    
PSUs | 2024 PSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Outstanding at beginning of period (in shares) 87,550    
Granted (in shares)   87,550  
Outstanding at end of period (in shares)   87,550  
Performance period 3 years 3 years  
PSUs | 2023 PSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Outstanding at beginning of period (in shares) 118,684    
Granted (in shares)     118,684
Outstanding at end of period (in shares)   118,684  
Performance period 3 years 3 years  
PSUs | 2022 PSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Outstanding at beginning of period (in shares) 133,034    
Outstanding at end of period (in shares)   133,034  
Performance period   3 years  
PSUs | 2025 PSUs      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]      
Granted (in shares) 86,911    
Performance period 3 years